Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
Bioventus (Nasdaq: BVS), a global leader in innovations for active healing, has scheduled its second quarter fiscal year 2025 earnings release and conference call. The company will announce its financial results before market open on Wednesday, August 6, 2025, followed by a management-hosted conference call at 8:30 a.m. Eastern Time.
Investors can participate by dialing 1-800-715-9871 (Conference ID: 1859022) or accessing the webcast through the company's investor relations website. The webcast recording will remain available for replay until August 5, 2026.
[]Bioventus (Nasdaq: BVS), leader globale nelle innovazioni per la guarigione attiva, ha programmato la pubblicazione dei risultati del secondo trimestre dell'anno fiscale 2025 e la relativa conference call. L'azienda annuncerà i risultati finanziari prima dell'apertura del mercato di mercoledì 6 agosto 2025, seguiti da una conference call condotta dal management alle 8:30 a.m. ora della costa orientale.
Gli investitori potranno partecipare chiamando il numero 1-800-715-9871 (ID conferenza: 1859022) oppure accedendo alla diretta streaming tramite il sito web delle relazioni con gli investitori dell'azienda. La registrazione della webcast rimarrà disponibile per la visione fino al 5 agosto 2026.
Bioventus (Nasdaq: BVS), líder mundial en innovaciones para la curación activa, ha programado la publicación de sus resultados del segundo trimestre del año fiscal 2025 y la correspondiente llamada de conferencia. La empresa anunciará sus resultados financieros antes de la apertura del mercado el miércoles 6 de agosto de 2025, seguida de una llamada de conferencia dirigida por la gerencia a las 8:30 a.m., hora del Este.
Los inversionistas pueden participar llamando al 1-800-715-9871 (ID de conferencia: 1859022) o accediendo a la transmisión web a través del sitio web de relaciones con inversionistas de la compañía. La grabación de la transmisión estará disponible para reproducción hasta el 5 de agosto de 2026.
Bioventus (나스닥: BVS)는 활발한 치유 혁신 분야의 글로벌 선두주자로서 2025 회계연도 2분기 실적 발표 및 컨퍼런스 콜 일정을 잡았습니다. 회사는 2025년 8월 6일 수요일, 시장 개장 전에 재무 결과를 발표하며, 이어서 동부 표준시 오전 8시 30분에 경영진 주최 컨퍼런스 콜이 진행됩니다.
투자자들은 1-800-715-9871 (회의 ID: 1859022)로 전화하거나 회사의 투자자 관계 웹사이트를 통해 웹캐스트에 참여할 수 있습니다. 웹캐스트 녹화는 2026년 8월 5일까지 다시 보기가 가능합니다.
Bioventus (Nasdaq : BVS), leader mondial dans les innovations pour la guérison active, a programmé la publication de ses résultats du deuxième trimestre de l'exercice 2025 ainsi qu'une conférence téléphonique. La société annoncera ses résultats financiers avant l'ouverture du marché, le mercredi 6 août 2025, suivis d'une conférence téléphonique animée par la direction à 8h30, heure de l'Est.
Les investisseurs peuvent participer en composant le 1-800-715-9871 (ID de la conférence : 1859022) ou en accédant au webcast via le site web des relations investisseurs de la société. L'enregistrement du webcast restera disponible en replay jusqu'au 5 août 2026.
Bioventus (Nasdaq: BVS), ein weltweit führendes Unternehmen für Innovationen im Bereich aktives Heilen, hat die Veröffentlichung der Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 sowie eine Telefonkonferenz geplant. Das Unternehmen wird seine Finanzergebnisse am Mittwoch, den 6. August 2025, vor Markteröffnung bekanntgeben, gefolgt von einer von der Geschäftsführung geleiteten Telefonkonferenz um 8:30 Uhr Eastern Time.
Investoren können teilnehmen, indem sie 1-800-715-9871 (Konferenz-ID: 1859022) anrufen oder über die Investor-Relations-Website des Unternehmens auf das Webcast zugreifen. Die Aufzeichnung des Webcasts wird bis zum 5. August 2026 zur Wiedergabe verfügbar sein.
- None.
- None.
DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 before the market opens on Wednesday, August 6, 2025. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.
To participate in the conference call, dial 1-800-715-9871 and refer either to the Bioventus Inc. Conference Call or the conference ID 1859022.
A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company's website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until August 5, 2026.
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.
Investor and Media Inquiries:
Dave Crawford
919-474-6787
Dave.Crawford@bioventus.com
FAQ
When will Bioventus (BVS) report Q2 2025 earnings?
How can investors join the Bioventus Q2 2025 earnings call?
What time is the Bioventus (BVS) Q2 2025 earnings conference call?
How long will the Bioventus Q2 2025 earnings webcast be available?
